{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-044293","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.162828+00:00","generated_at":"2026-06-17T03:04:08.464049+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Leap Therapeutics completes Part A enrollment (33 pts) in Phase 2 DeFianCe study of DKN-01 for colorectal cancer","bullets":["Part A enrolled 33 patients with advanced colorectal cancer; study is randomized, open-label, multicenter.","Part B is planned as a 130-patient randomized controlled trial; primary endpoint is progression-free survival.","Initial data from the study expected in mid-2023.","Secondary endpoints include overall response rate, duration of response, and overall survival."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-044293","json":"https://secwatch.observer/filing/0001104659-23-044293.json","markdown":"https://secwatch.observer/filing/0001104659-23-044293.md","text":"https://secwatch.observer/filing/0001104659-23-044293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923044293/0001104659-23-044293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923044293/tm2312449d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:04:08.464049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}